Journal
CANCER CELL
Volume 17, Issue 5, Pages 510-522Publisher
CELL PRESS
DOI: 10.1016/j.ccr.2010.03.017
Keywords
-
Categories
Funding
- NIH/NCI [U24 CA126561, U24 CA143882-01, P50CA127001]
- M.D. Anderson Center for Cancer Epigenetics
- Brain Tumor Funders' Collaborative
- V Foundation
- Rose Foundation
Ask authors/readers for more resources
We have profiled promoter DNA methylation alterations in 272 glioblastoma tumors in the context of The Cancer Genome Atlas (TCGA). We found that a distinct subset of samples displays concerted hypermethylation at a large number of loci, indicating the existence of a glioma-CpG island methylator phenotype (G-CIMP). We validated G-CIMP in a set of non-TCGA glioblastomas and low-grade gliomas. G-CIMP tumors belong to the proneural subgroup, are more prevalent among lower-grade gliomas, display distinct copy-number alterations, and are tightly associated with IDH1 somatic mutations. Patients with G-CIMP tumors are younger at the time of diagnosis and experience significantly improved outcome. These findings identify G-CIMP as a distinct subset of human gliomas on molecular and clinical grounds.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available